Jonathan Mandelbaum

Mirador 💪💪 goldmansachs.com/insights/goldm…

We're excited to announce positive feedback from our end-of-Phase 2 meeting with the FDA, supporting the development path forward for bitopertin in #EPP and highlighting the potential for accelerated approval. Join us for our webcast at 8am ET: ir.discmedicine.com/news-releases/…

news.abbvie.com/2024-10-28-Abb….

With $115M more, Triveni accelerates immune drug work biopharmadive.com/news/triveni-b… by @gwendolynawu #biotech #startups $REGN $APGE

@bmgallagherjr Baba O-Riley is up there

Greatest songs ever? I’m interested in what songs we all find motivating or otherwise. I will start and it’s really hard as I love so many artists… Foo Fighters came in close but have to say Rush takes the Cup (pun intended). Closer to the Heart is one of the greatest songs IMO

Prometheus team launches new startup with $400 million to tackle immune-driven disorders statnews.com/2024/03/21/bio… via @ADeAngelis_bio

Mirador debuts with $400M, picking up where immune drugmaker Prometheus left off biopharmadive.com/news/mirador-t… by @gwendolynawu $RXDX $MRK

This #RareDiseaseDay, join us in raising awareness for the 300 million people globally living with a rare disease, including those with erythropoietic porphyria (#EPP) and other hematologic disorders.

Triveni Bio Launches with $92 Million Series A Financing to Advance Genetics-Informed Precision Medicines for the Treatment of Immunological and Inflammatory (I&I) Disorders prnewswire.com/news-releases/…

OrbiMed is pleased to announce it has raised more than $4.3 billion in commitments for its latest private investment funds, including OrbiMed Private Investments IX, OrbiMed Asia Partners V and OrbiMed Royalty & Credit Opportunities IV. Read more here: orbimed.com/Data/Content/6…

OrbiMed portfolio company Aliada Therapeutics, along with Chiesi Global Rare Diseases, announces a co-development agreement to advance Aliada's blood-brain barrier-crossing platform technology in lysosomal storage disorders. Read more: prnewswire.com/news-releases/…

24 years ago today we played Woodstock ‘99. Here’s how we opened our set, with “Grace, Too”...

In data presented at #EHA2023, Disc announced initial positive results from BEACON, our Phase 2 clinical trial for bitopertin in #EPP. Read more: globenewswire.com/news-release/2…

Please join Disc as we host a virtual KOL investor event on Tuesday, April 25, 2023, at 1:00 pm ET / 10:00 am PT to provide an overview of our lead indication #EPP, a rare, severe disease caused by mutations in the heme biosynthesis pathway. globenewswire.com/en/news-releas…

Disc is pleased to announce the initiation of our Phase 1b/2 clinical study of DISC-0974 in non-dialysis dependent chronic kidney disease (NDD-CKD) patients with #anemia. Thanks to our fantastic R&D team in getting this study off the ground! globenewswire.com/en/news-releas…

Exciting year ahead for @DiscMedicine. Excellent article from @endpts on today's news: With a year full of readouts ahead, Disc Medicine secures cash from Bain Capital - endpts.com/disc-medicine-…

@michael_gilman So good!

Dude's a decent player.

Given yesterdays news of $AMGN buying $HZN for $28B I’ve been asked to give color to the Tepezza history by a few people in a Tweet Thread. So here it goes. It’s my fist so be kind.